Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-06-358226PMID 21976673PMCID PMC3234663
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term cardiac and pulmonary complications of cancer therapy.

  2011cited by this paper
• Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.

  2011cited by this paper
• Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

  2010cited by this paper
• Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

  2010cited by this paper
• Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

  2010cited by this paper
• The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls.

  2010cited by this paper
• Long‐term survival and late relapse in 2‐year survivors of autologous haematopoietic cell transplantation for Hodgkin and non‐Hodgkin lymphoma

  2009cited by this paper
• Cardiovascular disease after hematopoietic cell transplantation – lessons learned

  2008cited by this paper
• Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group

  2008cited by this paper
• Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention

  2008cited by this paper
• Long-term cardiac and pulmonary complications of cancer therapy.

  2008cited by this paper
• Late congestive heart failure after hematopoietic cell transplantation.

  2008cited by this paper
• Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation

  2008cited by this paper
• Late cardiotoxicity after treatment for Hodgkin lymphoma.

  2007cited by this paper
• National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.

  2007cited by this paper
• Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.

  2007cited by this paper
• Hematopoietic stem-cell transplantation.

  2006cited by this paper
• Hematopoietic stem-cell transplantation.

  2006cited by this paper
• Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

  2005cited by this paper
• Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.

  2005cited by this paper
• Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy

  2005cited by this paper
• Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls.

  2005cited by this paper
• Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations.

  2004cited by this paper
• World Wide Web at:

  2001cited by this paper
• Incidence and Epidemiology of Heart Failure

  2000cited by this paper
• Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

  2000cited by this paper
• Failure of women's hearts.

  1999cited by this paper
• Epidemiology of anthracycline cardiotoxicity in children and adults.

  1998cited by this paper
• The progression from hypertension to congestive heart failure.

  1996cited by this paper
• Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

  1995cited by this paper
• Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.

  1991cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations

  1986cited by this paper
• Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats.

  1985cited by this paper
• Tissue disposition of doxorubicin in experimental animals.

  1982cited by this paper
• Lung-cancer mortality as related to residence and smoking histories. I. White males.

  1962cited by this paper

• Long-term outcomes of hyperbaric oxygen pretreatment in autologous hematopoietic stem cell transplantation

  2026cites this paper
• Role of Cardio-Oncology Rehabilitation in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

  2025cites this paper
• Cardiovascular Considerations After Cancer Therapy

  2025cites this paper
• The utility of novel echocardiographic techniques in evaluating cardiac function in patients undergoing hematopoietic stem cell transplantation: a pilot study

  2025cites this paper
• Evaluation of Subclinical Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Hematopoietic Stem Cell Transplantation: An Echocardiography Study

  2024cites this paper
• Bag2 protects against doxorubicin-induced cardiotoxicity by maintaining Pink1-mediated mitophagy.

  2024cites this paper
• Cardio-Oncology and Heart Failure: A Scientific Statement from the Heart Failure Society of America.

  2024cites this paper
• Self‐rated health is an independent predictor of subsequent late mortality after blood or marrow transplantation: A Blood or Marrow Transplant Survivor Study report

  2024cites this paper
• Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults

  2024cites this paper
• Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation

  2024influential citation
• Echocardiographic Assessment of Right Ventricular Function and Pulmonary Arterial Pressure in Patients with Multiple Myeloma Post Autologous Hematopoietic Stem Cell Transplantation

  2024influential citation
• Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association.

  2024influential citation
• International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update

  2024cites this paper
• Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation

  2024cites this paper
• Early Impact of Mobilization Process on Cardiac Function and Size in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

  2024cites this paper
• Clonal Hematopoiesis and Risk of Heart Failure After Autologous Hematopoietic Cell Transplantation for Lymphoma

  2024cites this paper
• Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis

  2023cites this paper
• A prognostic model based on clinical biomarkers for heart failure in adult patients following allogeneic hematopoietic stem cell transplantation.

  2023cites this paper
• Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival

  2023cites this paper
• International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update

  2023cites this paper
• Cardiovascular diseases after high‐dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population‐based study

  2023influential citation
• Health care utilization by long‐term survivors of blood or marrow transplantation—A Bone Marrow Transplant Survivor Study report

  2023cites this paper
• Cardiovascular Events After Hematopoietic Stem Cell Transplant

  2023cites this paper
• Risky health behaviors and subsequent late mortality after blood or marrow transplantation: a BMTSS report

  2023cites this paper
• Survivors of Pediatric Hematopoietic Stem Cell Transplant Exhibit Progressive Diastolic Dysfunction Over Years of Follow-up.

  2023cites this paper
• Calculate Your Risk of Heart Attack After Hematopoietic Cell Transplantation

  2023cites this paper
• Cardiovascular toxicity from therapies for light chain amyloidosis

  2023cites this paper
• Inequity in care delivery in cardio-oncology: dissecting disparities in underrepresented populations

  2023cites this paper
• Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

  2023cites this paper
• Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group

  2022cites this paper
• Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients

  2022influential citation
• Cardiovascular diseases in patients after hematopoietic stem cell transplantation: Systematic review and Meta-analysis.

  2022cites this paper
• Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment

  2022cites this paper
• Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

  2022cites this paper
• Cardioprotection of High-Risk Individuals.

  2022cites this paper
• [Cardiac complications following allogeneic hematopoietic stem cell transplantation: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)].

  2022cites this paper
• Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies

  2022cites this paper
• Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Effect of hypertension on the optimal anthracycline cumulative dose for developing left ventricular dysfunction in patients with malignant lymphoma

  2022cites this paper
• Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022)

  2022cites this paper
• Sex-Specific Cardiovascular Risks of Cancer and Its Therapies

  2022cites this paper
• Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment

  2021cites this paper
• Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

  2021cites this paper
• Cardiovascular events and treatment of children with high risk medulloblastoma

  2021cites this paper
• Assessment of Early Cardiac Dysfunction Related to Cancer Therapy in Patients Receiving Hematopoietic Stem Cell Transplantation: An Echocardiographic Analysis

  2021cites this paper
• Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi

  2021influential citation
• Inequity in Cardio‐Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes

  2021cites this paper
• How I treat cardiovascular complications in patients with lymphoid malignancies.

  2021cites this paper
• Heart Failure in Long-Term Survivors of Childhood or Adolescent Cancers

  2021cites this paper
• A modified conditioning regimen based on low‐dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity

  2021cites this paper
• Cardiac complications associated with hematopoietic stem-cell transplantation

  2021cites this paper
• Recomendaciones para el manejo de la cardiotoxicidad relacionada con el tratamiento del cáncer. Primera parte

  2021cites this paper
• Interactions between cardiology and oncology drugs in precision cardio-oncology.

  2021cites this paper
• Critical Care of Hematopoietic Stem Cell Transplant Patients.

  2021cites this paper
• Molecular mechanisms of anthracycline cardiovascular toxicity.

  2021cites this paper
• Biology of survivorship after blood or marrow transplantation

  2021cites this paper
• Cardiac and arterial complications

  2021cites this paper
• Late effects post‐autologous hematopoietic stem cell transplantation

  2021cites this paper
• Case Series: Development of Polyps as a Late Effect After Total Body Irradiation-based Hematopoietic Cell Transplantation in Children With High-risk Leukemia

  2021cites this paper
• Using Statistical Methods to Predict Treatment Response Based on Patients' Likelihood of Having Benefits or Side Effects from the Treatment

  2020cites this paper
• Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

  2020cites this paper
• Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat.

  2020cites this paper
• Total Marrow Irradiation: A Comprehensive Review

  2020cites this paper
• Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System.

  2020cites this paper
• Late‐occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors

  2020cites this paper
• Reduced Intensity Conditioning Regimens in Combination with Total Marrow and Lymphoid Irradiation

  2020cites this paper
• Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant

  2020cites this paper
• Carfilzomib induced cardiotoxicity in a multiple myeloma patient

  2020cites this paper
• The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.

  2020cites this paper
• Left Ventricular Systolic Function in Long-Term Survivors of Allogeneic Hematopoietic Stem Cell Transplantation

  2020influential citation
• Acute Heart Failure 29 Years After Treatment for Childhood Cancer

  2020cites this paper
• Clinical Characteristics of Patients with Different N-Terminal Probrain Natriuretic Peptide Levels after Hematopoietic Stem Cell Transplantation

  2020cites this paper
• Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation

  2020cites this paper
• Conditional Survival, Cause-specific Mortality, Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.

  2020cites this paper
• Risk factors for chemotherapy-related cardiac toxicity

  2019cites this paper
• Looking for trouble: Reduced myocardial flow reserve following anthracyclines

  2019cites this paper
• Full Issue PDF

  2019cites this paper
• Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality after Allogeneic Hematopoietic Cell Transplantation

  2019cites this paper
• The Role of Echocardiography in Cardio-oncology Patients: Contemporary Indications and Future Directions

  2019cites this paper
• Title Cardiac Complications in the Adult Bone Marrow Transplant Patient Permalink

  2019cites this paper
• Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation

  2019cites this paper
• Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes

  2019cites this paper
• Miscellaneous Complications Related to Hematopoietic Cell Transplantation

  2019cites this paper
• Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation

  2019cites this paper
• Cardiac Complications in the Adult Bone Marrow Transplant Patient

  2019cites this paper
• Evaluation of Cardiac Parameters in Bone Marrow Transplant Patients: Effect of Pulmonary Artery Pressure on Survival

  2018cites this paper
• Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity

  2018cites this paper
• Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

  2018cites this paper
• Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

  2018cites this paper
• Prevalence of anthracycline‐related cardiac dysfunction in long‐term survivors of adult‐onset lymphoma

  2018cites this paper
• Heart Failure and Left Ventricular Dysfunction

  2018cites this paper
• Diabetes mellitus, blood glucose and the risk of heart failure: A systematic review and meta-analysis of prospective studies.

  2018cites this paper
• Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

  2018cites this paper
• Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation.

  2018cites this paper
• National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Cardiovascular Disease and Associated Risk Factors

  2017cites this paper